Global Acquired Hemophilia Treatment Market Size 2018 by Therapy (Inhibitor Eradication Therapy and Hemostatic Therapy), by Region and Forecast 2019 to 2025
Sep 2019
Total Pages: 80
Choose License Type
The global acquired hemophilia treatment market was valued at USD 2,181.7 million in 2018. Increasing geriatric population and excellent drug pharmocodynamic and pharmacokinetic profile exhibited by immunomodulatory therapy are the key drivers pertaining to acquired hemophilia treatment market growth.
As per the research findings brought forward by the National Organization for Rare Disorders (NORD) (U.S.), acquired hemophilia is a rare autoimmune disorder in which the immune system mistakenly produce antibodies against clotting factor VIII. The disease is mostly prevalent in geriatric population with mortality rate of around 21%, if untreated. Promising results highlighted by immunomodulatory agents in the phase III clinical trials, with excellent therapeutic index will eventually increase its popularity as the first line drug therapy to drastically reduce inhibitors pertaining to clotting factor VIII in the human blood serum. However, the high cost associated with bypassing agents employed as hemostatic therapy hinders the market penetration of acquired hemophilia treatment market in the low and middle income countries.
The global acquired hemophilia treatment market is majorly categorized as inhibitor eradication therapy and hemostatic therapy. The inhibitor eradication therapy is further sub-segmented as steroid treatment, cytotoxic treatment and immunomodulatory therapy. Hemostatic therapy comprises desmopressin and Obizur, frequently employed to manage minor bleeding complications; whereas, NovoSeven RT and FEIBA are used to manage major bleeding complications. Hemostatic therapy spearheaded the treatment segment in 2018, with 50.8% market share.
North America dominated the global market for acquired hemophilia treatment representing a revenue share of 35.4% in 2018. Asia Pacific is anticipated to exhibit rapid growth during the forecast period on account of the rising prevalence of acquired hemophilia in elderly population; and existence of lucrative business opportunity for western giants to establish subsidiaries.
The key biopharmaceutical companies actively engaged in the manufacturing of drugs employed for the treatment of acquired hemophilia are Baxter Healthcare Corporation, BioXcel Corporation, Genetech, Inc., GlaxoSmithkline, Plc., Ferring B.V., Mylan N.V., Novo Nordisk, Sanofi SA, Shire, Plc. and Teva Pharmaceutical Industries Ltd.
Key Segments of the Acquired Hemophilia Treatment Market
By Therapy, 2015-2025 (USD Million)
- Inhibitor Eradication Therapy
- Steroids
- Cytotoxic Agents
- Immunomodulatory Agents
- Hemostatic Therapy
- Desmopressin
- Recombinant Activated Factor VII/NovoSeven RT
- Recombinant Activated Factor VIII/Obizur
- Activated Prothrombin Complex Concentrate (aPCC)/FEIBA
Regional Overview, 2015-2025 (USD Million)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Rest of MEA
Reasons for the study
- The purpose of the study is to give a holistic outlook of the global acquired hemophilia treatment market
- The overall segmentation of the acquired hemophilia treatment market, especially key segments such as therapy type is thoroughly studied. Inhibitor eradication therapy is anticipated to be the fastest growing sub segment till 2025
- FastTrack status awarded by local healthcare authorities for the drug development pertaining to rare and orphan disease in Asia Pacific will further drive the acquired hemophilia treatment market growth
- Rising prevalence of acquired hemophilia and implementation of effective treatment guidelines will further propel the acquired hemophilia treatment market growth
What does the report include?
- The study on the global acquired hemophilia treatment market includes qualitative analysis of factors such as drivers, restraints and opportunities
- The report covers qualitative and quantitative analysis of the overall market segmented on the basis of therapy type and breakdown of the same at regional level
- Actual market size and forecast have been provided for all the considered segments
- The study includes the profiles of key market players with a significant global and/or regional presence along with top company positioning
Who should buy this report?
This study is suitable for industry participants and stakeholders in the drug development of rare diseases, seeking an in-depth insight into the movement of the acquired hemophilia treatment market. The report will benefit:
- Executives of biopharmaceutical companies that are engaged in the development of medicines for the treatment of acquired hemophilia
- Managers within financial institutions looking to publish recent and forecasted statistics pertaining to acquired hemophilia treatment regimen
- Venture capitalists, investors, financial institutions, analysts, government organizations, regulatory authorities, policymakers, researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies
- Manufacturers of medicines pertaining to rare diseases who are looking for new avenues of revenue generation
The prevalence rate of acquired hemophilia is highly variable ranging from 0.045 per million in children to 14.7 per million adult population. It is an autoimmune disorder in which immunoglobulin G antibodies bind to the clotting factor VIII thereby drastically delaying the blood clotting time, which if not treated promptly may lead to fatal health complications. The mortality rate associate with acquired hemophilia is approximately 21%, caused due to incessant bleeding due to haemorrhage of internal organs. The diagnosis of acquired hemophilia is complicated owing to the overlapping symptoms with other autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, multiple sclerosis, allergic drug reactions etc.
Currently, physicians worldwide are adopting a two pronged strategy for treating acquired hemophilia patients, eradicating the inhibitor against clotting factor VIII and control bleeding. Methyl prednisolone is started immediately alone or in combination with cytotoxic agents such as cyclophosphamide, azathioprine, cyclosporine and other immunosuppressant to reduce the inhibitor titer volume to facilitate blood clotting. At present, monoclonal antibodies such as rituximab and emicizumab are being investigated in phase 3 clinical trials for its therapeutic efficacy in reducing the inhibitor titre volume in the blood plasma, based on the positive results it is anticipated to become the first line therapy for treating acquired hemophilia.
The most important aspect is to control bleeding in patients hospitalized for haemorrhage of vital organs. Desmopressin is usually prescribed in minor bleeding cases with low inhibitor titre in blood plasma. FEIBA having half-life of 4-7 hours and NovoSeven RT with half-life of 2 hours are the bypassing agents, which are the first line therapy adopted in patients suffering with severe bleeding with high inhibitor titre volume. Administration of 200 U/kg of Obizur has shown positive clinical outcomes with therapeutic levels of factor VIII restored in the blood plasma showcasing 86% success rate. Obizur is anticipated to show promising results in the near future for its therapeutic efficacy in treating acquired hemophilia.
The global acquired hemophilia treatment market is segmented as hemostatic therapy for controlling the incessant bleeding due to hemorrhage and inhibitor eradication therapy to increase the blood serum levels of clotting factor VIII. Inhibitor eradication therapy comprises steroids such as methyl prednisolone which is used alone or in combination with cytotoxic agent such as cyclophosphamide or other immunosuppressant as the first line therapy to reduce the inhibitor titer in the blood serum against clotting factor VIII. Rituximab, Emicizumab etc., are the immunomodulation agents which are used as second line therapy in patients showing resistance to combination therapy of steroid and cytotoxic agents. It represents a market share of 49.2% in 2018 and is anticipated to be the fastest growing segment during the forecast period. Hemostatic therapy consists of desmopressin, NovoSeven RT, Obizur and FEIBA, which are primarily employed to stop the bleeding due to hemorrhage in patients suffering with acquired hemophilia.
.png "Global Acquired Hemophilia Treatment Market, By Therapy (USD Million)")
The global acquired hemophilia treatment market is spread across North America, Europe, Asia Pacific, South America and Middle East & Africa. North America is the largest regional segment for global acquired hemophilia treatment market. The major parameters responsible for its positive market growth are rising public health awareness resulting in early disease diagnosis and treatment for acquired hemophilia. Supportive reimbursement scenario for the medicines prescribed for the treatment of acquired hemophilia further fortifies the market growth in the region. Europe is placed in the second position due to supportive regulatory environment provided by the European Medical Agency (EMA) by approving FastTrack designation for the drug discovery and development of medicines for treating acquired hemophilia. Asia Pacific is expected to grow at a CAGR of 5.4% in the near future, primarily due to constant rise in elderly population suffering with acquired hemophilia.
.png "Acquired Hemophilia Treatment Market, By Region (USD Million)")
The global acquired hemophilia treatment market was valued at USD 2,181.7 million in 2018. Increasing geriatric population and excellent drug pharmocodynamic and pharmacokinetic profile exhibited by immunomodulatory therapy are the key drivers pertaining to acquired hemophilia treatment market growth.
As per the research findings brought forward by the National Organization for Rare Disorders (NORD) (U.S.), acquired hemophilia is a rare autoimmune disorder in which the immune system mistakenly produce antibodies against clotting factor VIII. The disease is mostly prevalent in geriatric population with mortality rate of around 21%, if untreated. Promising results highlighted by immunomodulatory agents in the phase III clinical trials, with excellent therapeutic index will eventually increase its popularity as the first line drug therapy to drastically reduce inhibitors pertaining to clotting factor VIII in the human blood serum. However, the high cost associated with bypassing agents employed as hemostatic therapy hinders the market penetration of acquired hemophilia treatment market in the low and middle income countries.
The global acquired hemophilia treatment market is majorly categorized as inhibitor eradication therapy and hemostatic therapy. The inhibitor eradication therapy is further sub-segmented as steroid treatment, cytotoxic treatment and immunomodulatory therapy. Hemostatic therapy comprises desmopressin and Obizur, frequently employed to manage minor bleeding complications; whereas, NovoSeven RT and FEIBA are used to manage major bleeding complications. Hemostatic therapy spearheaded the treatment segment in 2018, with 50.8% market share.
North America dominated the global market for acquired hemophilia treatment representing a revenue share of 35.4% in 2018. Asia Pacific is anticipated to exhibit rapid growth during the forecast period on account of the rising prevalence of acquired hemophilia in elderly population; and existence of lucrative business opportunity for western giants to establish subsidiaries.
The key biopharmaceutical companies actively engaged in the manufacturing of drugs employed for the treatment of acquired hemophilia are Baxter Healthcare Corporation, BioXcel Corporation, Genetech, Inc., GlaxoSmithkline, Plc., Ferring B.V., Mylan N.V., Novo Nordisk, Sanofi SA, Shire, Plc. and Teva Pharmaceutical Industries Ltd.
Key Segments of the Acquired Hemophilia Treatment Market
By Therapy, 2015-2025 (USD Million)
- Inhibitor Eradication Therapy
- Steroids
- Cytotoxic Agents
- Immunomodulatory Agents
- Hemostatic Therapy
- Desmopressin
- Recombinant Activated Factor VII/NovoSeven RT
- Recombinant Activated Factor VIII/Obizur
- Activated Prothrombin Complex Concentrate (aPCC)/FEIBA
Regional Overview, 2015-2025 (USD Million)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Rest of MEA
Reasons for the study
- The purpose of the study is to give a holistic outlook of the global acquired hemophilia treatment market
- The overall segmentation of the acquired hemophilia treatment market, especially key segments such as therapy type is thoroughly studied. Inhibitor eradication therapy is anticipated to be the fastest growing sub segment till 2025
- FastTrack status awarded by local healthcare authorities for the drug development pertaining to rare and orphan disease in Asia Pacific will further drive the acquired hemophilia treatment market growth
- Rising prevalence of acquired hemophilia and implementation of effective treatment guidelines will further propel the acquired hemophilia treatment market growth
What does the report include?
- The study on the global acquired hemophilia treatment market includes qualitative analysis of factors such as drivers, restraints and opportunities
- The report covers qualitative and quantitative analysis of the overall market segmented on the basis of therapy type and breakdown of the same at regional level
- Actual market size and forecast have been provided for all the considered segments
- The study includes the profiles of key market players with a significant global and/or regional presence along with top company positioning
Who should buy this report?
This study is suitable for industry participants and stakeholders in the drug development of rare diseases, seeking an in-depth insight into the movement of the acquired hemophilia treatment market. The report will benefit:
- Executives of biopharmaceutical companies that are engaged in the development of medicines for the treatment of acquired hemophilia
- Managers within financial institutions looking to publish recent and forecasted statistics pertaining to acquired hemophilia treatment regimen
- Venture capitalists, investors, financial institutions, analysts, government organizations, regulatory authorities, policymakers, researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies
- Manufacturers of medicines pertaining to rare diseases who are looking for new avenues of revenue generation
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data sources
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. Market drivers
3.2.1.1. Constant rise in acquired hemophilia in elderly population worldwide
3.2.1.2. Excellent pharmacodynamics and pharmacokinetic profiles exhibited by immunomodulatory agents employed as inhibitor eradication therapy
3.2.2. Market restraints
3.2.2.1. Overlapping symptoms with other autoimmune diseases results in 70% of patients remaining undiagnosed throughout their lifetime
3.2.2.2. High cost associated with bypassing agents employed in hemostatic therapy hinders its market penetration in low and middle income economies
3.2.3. Market opportunities
3.2.3.1. Effective implementation of treatment guidelines in the developing regions will further accentuate the acquired haemophilia treatment market growth
3.3. Top player positioning, 2018
Chapter 4. Acquired Hemophilia Treatment Market Overview, By Therapy Type
4.1. Inhibitor eradication therapy
4.1.1. Steroids
4.1.2. Cytotoxic agents
4.1.3. Immunomodulatory agents
4.2. Hemostatic therapy
4.2.1. Desmopressin
4.2.2. Recombinant activated factor VII/NovoSeven RT
4.2.3. Recombinant activated factor VIII/Obizur
4.2.4. Activated prothrombin complex concentrate (aPCC)/FEIBA
Chapter 5. Acquired hemophilia treatment Market Overview, By Region
5.1. North America
5.1.1. U.S.
5.1.2. Canada
5.2. Europe
5.2.1. U.K.
5.2.2. Germany
5.2.3. Rest of Europe
5.3. Asia Pacific
5.3.1. China
5.3.2. Japan
5.3.3. Rest of Asia Pacific
5.4. Latin America
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. MEA
5.5.1. GCC
5.5.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Baxter Healthcare Corporation
6.1.1. Company overview
6.1.2. Product portfolio
6.1.3. Key developments
6.1.4. Financial performance
6.2. BioXcel Corporation
6.2.1. Company overview
6.2.2. Product portfolio
6.2.3. Key developments
6.2.4. Financial performance
6.3. Genetech, Inc.
6.3.1. Company overview
6.3.2. Product portfolio
6.3.3. Key developments
6.3.4. Financial performance
6.4. GlaxoSmithkline, Plc.
6.4.1. Company overview
6.4.2. Product portfolio
6.4.3. Key developments
6.4.4. Financial performance
6.5. Ferring B.V.
6.5.1. Company overview
6.5.2. Product portfolio
6.5.3. Key developments
6.5.4. Financial performance
6.6. Mylan N.V.
6.6.1. Company overview
6.6.2. Product portfolio
6.6.3. Key developments
6.6.4. Financial performance
6.7. Novo Nordisk
6.7.1. Company overview
6.7.2. Product portfolio
6.7.3. Key developments
6.7.4. Financial performance
6.8. Sanofi SA
6.8.1. Company overview
6.8.2. Product portfolio
6.8.3. Key developments
6.8.4. Financial performance
6.9. Shire, Plc.
6.9.1. Company overview
6.9.2. Product portfolio
6.9.3. Key developments
6.9.4. Financial performance
6.10. Teva Pharmaceutical Industries Ltd.
6.10.1. Company overview
6.10.2. Product portfolio
6.10.3. Key developments
6.10.4. Financial performance